What is Scott Cundy’s current role at Medtronic related to MiniMed (MMED)?

Scott Cundy is Senior Vice President and Chief Quality, Development, and Innovation Officer at Medtronic. He leads Global Quality, Product Development, and Innovation, oversees the Medtronic Engineering and Innovation Center, and is a member of the Medtronic Executive Committee, bringing operating experience to MiniMed’s Board.

MiniMed updates Board with new Medtronic executive

MiniMed Group, Inc. reported that director Brett Wall, a class II member of the Board and of the Nominating and Corporate Governance Committee, has notified the company he will resign from the Board effective July 3, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

MiniMed Group, Inc. reported that director Brett Wall, a class II member of the Board and of the Nominating and Corporate Governance Committee, has notified the company he will resign from the Board effective July 3, 2026. The company states his decision is not due to any disagreement with management or the Board, but follows his departure from a senior leadership role at Medtronic plc, MiniMed’s parent, which originally nominated him.

To fill the vacancy, Scott Cundy was appointed as a director effective July 3, 2026. He will serve as a class II director with a term expiring at the 2027 annual meeting of stockholders and will join the Nominating and Corporate Governance Committee. Cundy is a senior Medtronic executive overseeing global quality, product development, and innovation. While Medtronic remains an affiliate of MiniMed, he will receive no compensation for Board service; if that changes, his pay will align with MiniMed’s non‑employee director program.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Wall resignation effective date: July 3, 2026 Cundy appointment date: July 3, 2026 Cundy Board term end: 2027 annual meeting +1 more

4 metrics

Wall resignation effective date July 3, 2026 Effective date of Brett Wall’s Board resignation

Cundy appointment date July 3, 2026 Effective date of Scott Cundy’s Board appointment

Cundy Board term end 2027 annual meeting End of Scott Cundy’s initial term as class II director

Exhibit 104 Cover Page Interactive Data File Inline XBRL cover page data file listed in exhibit index

Key Terms

class II director, Nominating and Corporate Governance Committee, emerging growth company, Regulation S-K, +1 more

5 terms

class II director regulatory

"Brett Wall, a class II director of the Board of Directors"

A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.

Nominating and Corporate Governance Committee regulatory

"and member of the Board’s Nominating and Corporate Governance Committee"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Regulation S-K regulatory

"material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K"

A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

affiliate financial

"For so long as Medtronic is an affiliate of MiniMed, Mr. Cundy, as an employee of Medtronic, will receive no compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is MiniMed (MMED) director Brett Wall resigning from the Board?

Brett Wall is resigning effective July 3, 2026 because he is leaving his role at Medtronic plc, MiniMed’s parent, which originally nominated him. The company states his decision is not due to any disagreement with management or the Board.

Who is replacing Brett Wall on MiniMed (MMED)’s Board of Directors?

MiniMed has appointed Scott Cundy to its Board effective July 3, 2026. He will serve as a class II director and join the Nominating and Corporate Governance Committee, filling the vacancy created by Brett Wall’s resignation from the Board.

What is Scott Cundy’s term as a MiniMed (MMED) director?

Scott Cundy will serve as a class II director with a term expiring at MiniMed’s 2027 annual meeting of stockholders. His appointment is effective July 3, 2026, when he fills the Board seat vacated by director Brett Wall.

Will MiniMed (MMED) pay Board fees to Scott Cundy immediately?

For as long as Medtronic remains an affiliate of MiniMed, Scott Cundy will receive no compensation for his Board service because he is a Medtronic employee. If that relationship changes, his director compensation will match that of other non‑employee MiniMed directors.

Does Scott Cundy have any related‑party transactions with MiniMed (MMED)?

The company states that Scott Cundy does not have a material interest in any transaction requiring disclosure under Item 404(a) of Regulation S‑K, and there is no arrangement or understanding pursuant to which he was selected as a director of the Board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/18/2026 - 05:09 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2026

MiniMed Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-43183	33-3985981
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

18000 Devonshire St.

Northridge, CA 91325

(Address of principal executive offices) (Zip Code)

(763) 514-4000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.01 par value		MMED		The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) and member of the Board’s Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026. His decision to resign is not the result of any disagreement with management or the Board related to MiniMed’s operations, policies, or practices. His decision to resign results from his departure as Executive Vice President and President, Neuroscience Portfolio, of Medtronic plc (“Medtronic”), the parent company of MiniMed, which nominated Mr. Wall as a member of the Board.

On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall’s departure. Mr. Cundy will serve as class II director whose term expires at the 2027 annual meeting of stockholders and will be a member of the Board’s Nominating and Corporate Governance Committee.

Mr. Cundy currently serves as Senior Vice President and Chief Quality, Development, and Innovation Officer at Medtronic, leads the Global Quality, Product Development, and Innovation functions at Medtronic and is a member of the Medtronic Executive Committee. Mr. Cundy also oversees the Medtronic Engineering and Innovation Center. Prior to joining Medtronic in 2023, Mr. Cundy served as Vice President Quality, Regulatory, & Clinical Affairs Diagnostics and Life Sciences Platforms at Danaher Corporation. Mr. Cundy holds a B.S. in Industrial Engineering from Georgia Institute of Technology and an MBA from the University of Minnesota’s Carlson School of Management.

Mr. Cundy does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K, and there is no arrangement or understanding pursuant to which he was selected as a director of the Board.

For so long as Medtronic is an affiliate of MiniMed, Mr. Cundy, as an employee of Medtronic, will receive no compensation for his service on the Board. Thereafter, Mr. Cundy’s compensation for service as a director will be consistent with the compensation paid to other non-employee directors of MiniMed as described in MiniMed’s Form 8-K filed with the Securities and Exchange Commission on March 9, 2026.

Item 9.01	Exhibits

Exhibit Number	Description

104	Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MiniMed Group, Inc.

Date: May 18, 2026	By:	/s/ Bryan F. Kelly
	Name:	Bryan F. Kelly
	Title:	Senior Counsel, Securities & Corporate Governance, Assistant Corporate Secretary

EXHIBIT INDEX

Exhibit Number		Description

104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents